With "so many things going on in our biotechnology industry," Mike Narachi said he had his pick of opportunities following the shutdown of Orexigen Therapeutics Inc., whose obesity drug, Contrave (naltrexone HCl/bupropion HCl), went to Pernix Therapeutics Holdings Inc. at the end of July following bankruptcy proceedings.